Table of Contents FORM 6-K ________________________________________ U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2023 ________________________________________ TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) ________________________________________ 1 ...

| --- | --- | --- | --- | --- | --- | |------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | TSE: 4502 | | | | | | | | | | | | | | | | | | | | | | | | | | | | Committed to Growth & | | | | | | | Shareholder Returns | | | | | | | FY2023 Q3 Earnings Announcement February 1 st , 2024 | | | | | | | | | | | | | Important Notice For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and a ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2023 Earnings Conference Call February 2, 2023 5:30 AM ET Company Participants Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Andy Plump - President, R&D Costa Saroukos - Chief Financial Officer Ramona Sequeira - President, Global Portfolio Division Conference Call Participants Hidemaru Yamaguchi - Citigroup Motoya Koutani - Nomura Securities Seiji Wakao - JPMorgan Shinichiro Muraoka - Morgan Stanle ...

Committed to Long-term Growth & Shareholder Returns 41st Annual J.P. Morgan Healthcare Conference Christophe Weber President & CEO January 9th, 2023 Important Notice For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in conne ...

| --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------| | | | | | | TSE: 4502 | | | | | | | | | | | | | | | | | | | | Better health for people, Brighter future for the world | | | | | | | | | | FY2022 Q2 Earnings Announcement October 27 th , 2022 | | | | IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by ...

Better health for people, Brighter future for the world February 3, 2022 FY2021 Q3 EARNINGS ANNOUNCEMENT IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does ...

Takeda Pharmaceutical Company Limited. (NYSE:TAK) Q3 2022 Earnings Conference Call February 3, 2022 6:00 AM ET Corporate Participants Christopher OÂ'Reilly - Global Head, IR & Global Finance Christophe Weber - President and Chief Executive Officer Andy Plump - President Research and Development Costa Saroukos - Chief Financial Officer Masato Iwasaki - Japan General Affairs Ramona Sequeira - President, U.S. Business Unit and Global Portfolio Commercialization Julie Kim - President, Plasma-Derived Therapies B ...

| --- | --- | --- | --- | |-------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Better health for people, | | | | | Brighter future for the world | | | | Important Notice For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2022 Earnings Conference Call October 28, 2021 5:30 AM ET Company Participants Christopher OÂ'Reilly - Global Head, IR & Global Finance Christophe Weber - President and CEO Andy Plump - President Research and Development Costa Saroukos - CFO Masato Iwasaki - Japan General Affairs Ramona Sequeira - President, U.S. Business Unit and Global Portfolio Commercialization Julie Kim - President, Plasma-Derived Therapies Business Unit Conference Call Participants H ...

Takeda Pharmaceutical Co Ltd (NYSE:TAK) Q1 2022 Earnings Conference Call July 30, 2021 6:00 AM ET Company Participants Christopher O'Reilly - Global Head, IR & Global Finance Christophe Weber - President & CEO Andrew Plump - President, Research & Development Constantine Saroukos - CFO Masato Iwasaki - Representative Director Julie Kim - President, Plasma-Derived Therapies Business Unit Ramona Sequeira - President, US Business Unit & Global Portfolio Commercialization Conference Call Participants Hidemaru Ya ...